Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The dendritic cell antigen presentation pathway refers to the series of cellular and molecular events by which dendritic cells (DCs) capture, process, and present antigens to T lymphocytes. Dendritic cells are considered the most efficient antigen-presenting cells (APCs) in the immune system, playing a central role in initiating adaptive immune responses and establishing immunological tolerance. This pathway involves antigen uptake, processing into peptides, loading onto MHC molecules (MHC I and MHC II), and presentation to T cells, accompanied by co-stimulatory signals and cytokine secretion. Key processes include classical MHC II presentation to CD4+ T cells, and cross-presentation of exogenous antigens on MHC I to activate CD8+ T cells. Activation of DCs via PRRs like TLRs regulates the pathway, impacting immune responses in cancer, infection, and autoimmunity.
N/A - This is a pathway, not a single molecule.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dendritic Cell Antigen Presentation Pathway (DC Antigen Presentation).